---
figid: PMC5540723__jgo-28-e64-g001
figtitle: PD-1 pathway signaling and the targeting of the PD-1 pathway during cancer
  immunotherapy
organisms:
- NA
pmcid: PMC5540723
filename: jgo-28-e64-g001.jpg
figlink: /pmc/articles/PMC5540723/figure/F1/
number: F1
caption: PD-1 pathway signaling and the targeting of the PD-1 pathway during cancer
  immunotherapy. T cells recognize the MHC-antigen complex through TCR. CD28 binds
  to CD80/86 and mediates an activation signal through the PI3K or Ras pathways. PD-1
  is ligated with PD-L1 recruitments of SHP-2, which dephosphorylates the downstream
  molecules and blocks T cell activation. The PD-1 and PD-L1 blockade with mAbs can
  enhance T cell antitumor activity [].APC, antigen-presenting cell; CD, cluster of
  differentiation; mAbs, monoclonal antibodies; MHC, major histocompatibility complex;
  PD-1, programmed death-1; PD-L1, programmed death-ligand 1; PI3K, phosphatidylinositol
  3-kinase; SHP-2, Src homology region 2 domain-containing phosphatase-2; TCR, T cell
  receptor.
papertitle: 'Programmed death-1 pathway blockade produces a synergistic antitumor
  effect: combined application in ovarian cancer.'
reftext: Xinxin Zhu, et al. J Gynecol Oncol. 2017 Sep;28(5):e64.
year: '2017'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9504324
figid_alias: PMC5540723__F1
figtype: Figure
organisms_ner:
- Homo sapiens
redirect_from: /figures/PMC5540723__F1
ndex: 3505214b-dea5-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5540723__jgo-28-e64-g001.html
  '@type': Dataset
  description: PD-1 pathway signaling and the targeting of the PD-1 pathway during
    cancer immunotherapy. T cells recognize the MHC-antigen complex through TCR. CD28
    binds to CD80/86 and mediates an activation signal through the PI3K or Ras pathways.
    PD-1 is ligated with PD-L1 recruitments of SHP-2, which dephosphorylates the downstream
    molecules and blocks T cell activation. The PD-1 and PD-L1 blockade with mAbs
    can enhance T cell antitumor activity [].APC, antigen-presenting cell; CD, cluster
    of differentiation; mAbs, monoclonal antibodies; MHC, major histocompatibility
    complex; PD-1, programmed death-1; PD-L1, programmed death-ligand 1; PI3K, phosphatidylinositol
    3-kinase; SHP-2, Src homology region 2 domain-containing phosphatase-2; TCR, T
    cell receptor.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - APC
  - PROC
  - CD86
  - CD80
  - CD274
  - CD28
  - PDCD1
  - RPL17
  - RPL17-C18orf32
  - TRBV20OR9-2
  - TRA
  - TRB
  - TRD
  - TRG
  - PTPN11
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - KRAS
  - HRAS
  - NRAS
  - AKT1
  - AKT2
  - AKT3
  - Cancer
---
